Felodipine in the treatment of severe refractory hypertension

Naomi Nussinovitch*, J. Carroll, A. Shamiss, E. Grossman, A. Katz, C. Rachima, T. Rosenthal

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

The efficacy of felodipine and tolerance of this drug was examined in 52 patients, 23 men and 29 women, 18-76 years of age, in whom it either replaced previous therapies of nifedipine and other vasodilators, or was added to a constant dose of beta blockers and diuretics or another previous therapy, which was unchanged. Felodipine significantly reduced blood pressure (BP), from 192.3 ± 31.9/114.3 ± 18.0 to 155.7 ± 19.5/93.8 ± 11.5 mmHg, with no change in pulse rate. There were no significant biochemical changes, renal deterioration or blood sugar disequilibrium. Adverse reactions including flushes and leg edema could be tolerated by most of the patients, however six patients dropped out. Orthostasis dictated a decrease in felodipine dosage. Felodipine appears to be a highly potent, well tolerated drug and offers a substitute treatment for severe hypertensives refractory to other vasodilators.

Original languageEnglish
Pages (from-to)S165-S167
JournalJournal of Human Hypertension
Volume10
Issue numberSUPPL. 3
StatePublished - 1996

Keywords

  • Felodipine
  • Refractory hypertension

Fingerprint

Dive into the research topics of 'Felodipine in the treatment of severe refractory hypertension'. Together they form a unique fingerprint.

Cite this